{"transactions":[{"id":996281,"issuer":{"id":7735,"kind":"organization","name":"Q/C TECHNOLOGIES, INC.","symbol":"QCLS"},"owners":[{"id":8256,"kind":"organization","name":"PharmaCyte Biotech, Inc.","position":1,"cik":"0001157075","reported_name":"PharmaCyte Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-11-18T21:32:29.000Z","date":"2025-11-14","kind":"purchase","planned":false,"acquired":true,"shares":889865,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."},{"field":"date","element":"transactionDate","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."}],"balance_after":889865,"derivative":{"expiration_date":"2030-11-14","underlying":"Common stock, par value $0.001 per share","underlying_shares":889865},"source":{"system":"sec-edgar","filing":"0001683168-25-008517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316825008517/ownership.xml","form_type":"4"}},{"id":996280,"issuer":{"id":7735,"kind":"organization","name":"Q/C TECHNOLOGIES, INC.","symbol":"QCLS"},"owners":[{"id":8256,"kind":"organization","name":"PharmaCyte Biotech, Inc.","position":1,"cik":"0001157075","reported_name":"PharmaCyte Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series H Convertible Preferred Stock","published_at":"2025-11-18T21:32:29.000Z","date":"2025-09-04","kind":"purchase","planned":false,"acquired":true,"shares":889865,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."},{"field":"date","element":"transactionDate","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire."}],"balance_after":889865,"derivative":{"underlying":"Common stock, par value $0.001 per share","underlying_shares":889865},"source":{"system":"sec-edgar","filing":"0001683168-25-008517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316825008517/ownership.xml","form_type":"4"}}]}